Form 8-K - Current report:
SEC Accession No. 0001654954-24-014203
Filing Date
2024-11-13
Accepted
2024-11-13 08:15:36
Documents
17
Period of Report
2024-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tenx_8k.htm   iXBRL 8-K 24334
2 PRESS RELEASE tenx_ex991.htm EX-99.1 85139
8 tenx_ex991img1.jpg GRAPHIC 2768
  Complete submission text file 0001654954-24-014203.txt   246360

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tenx-20241113.xsd EX-101.SCH 5874
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tenx-20241113_lab.xml EX-101.LAB 14667
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE tenx-20241113_cal.xml EX-101.CAL 898
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tenx-20241113_pre.xml EX-101.PRE 9275
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tenx-20241113_def.xml EX-101.DEF 2099
19 EXTRACTED XBRL INSTANCE DOCUMENT tenx_8k_htm.xml XML 3910
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Filer) CIK: 0000034956 (see all company filings)

EIN.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34600 | Film No.: 241451295
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)